Immix Biopharma (IMMX) Net Income towards Common Stockholders (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 122.05% year-over-year to -$10.1 million; the trailing twelve-month figure through Mar 2026 stood at -$26.7 million (down 3259.47% YoY), and the FY2025 full-year result was -$21.2 million, down 1236.49% from the prior year.
• Net Income towards Common Stockholders slipped to -$10.1 million in Q1 2026, from -$2.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $15.3 million in Q4 2024 to a low of -$10.1 million in Q1 2026.
• A 5-year average of -$3.0 million and a median of -$3.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 649.04% in 2022 and surged 1965.89% in 2024, its largest moves.
• Tracing IMMX's Net Income towards Common Stockholders over 5 years: stood at -$2.1 million in 2022, then surged by 60.06% to -$820134.0 in 2023, then surged by 1965.89% to $15.3 million in 2024, then tumbled by 115.77% to -$2.4 million in 2025, then slumped by 317.98% to -$10.1 million in 2026.
• Business Quant data shows IMMX's Net Income towards Common Stockholders at -$10.1 million in Q1 2026, -$2.4 million in Q4 2025, and -$7.6 million in Q3 2025.